If you would like to be considered for a clinical trial, you will require a referral from your current treating team. Visit the Joining a clinical trial page for referral information. For more information on indolent non-hodgkin lymphoma and T-cell lymphoproliferative disease clinical trials, get in contact with our Haem B team This email address is being protected from spambots. You need JavaScript enabled to view it..Open and Recruiting Clinical Trials
PLATYPS
A Phase I, Open-Label, Single Arm Trial to Assess the Efficacy and Safety of PMCC-COE19 in Patients with CD19-Expressing B-Cell Malignancies
Trial IDACTRN12625001195448Cancer typeB-cell malignanciesStatusOpen to recruitmentPhasePhase one: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one clinical trial is to test the safety of the new treatment and find the best dose to give patientsWho can participateClinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.For full inclusion / exclusion criteria refer to the Australian Clinical Trials Registry.
Lumi-NHL / D9890C00001
A modular Phase I/II, open-label, multi-center study to evaluate the safety, pharmacokinetics, pharmacodynamics, immunogenicity and efficacy of AZD4512 monotherapy or in combination with anti-cancer agent(s) in participants with relapsed/refractory B-cell Non-Hodgkin Lymphoma (B-NHL) (Lumi-NHL)
Trial IDNCT07123454Cancer typeB-cell Non-Hodgkin LymphomaStatusOpen to recruitmentPhasePhase one / two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two-part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancer Who can participateClinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.For full inclusion / exclusion criteria refer to the Australian Clinical Trials Registry.
Moonshot / ALLG CLL11
An ALLG phase II trial of Epcoritamab consolidation in high genomic risk and MRD+ CLL patients after first-line venetoclax + obinutuzumab
Trial IDACTRN12625000387426Cancer typeChronic lymphocytic leukaemiaStatusOpen to recruitmentPhasePhase Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types Who can participateClinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.For full inclusion / exclusion criteria refer to the Australian Clinical Trials Registry.
BGB-16673-304
A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Trial IDNCT06973187Cancer typeChronic Lymphocytic Leukemia or Small Lymphocytic LymphomaStatusOpen to recruitmentPhasePhase three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to existing treatments available for that cancer typeWho can participateClinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.For full inclusion / exclusion criteria refer to the Australian Clinical Trials Registry.
CELESTIAL-RRCLL / BGB-11417-303
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Trial IDNCT06943872Cancer typeChronic Lymphocytic Leukemia or Small Lymphocytic LymphomaStatusOpen to recruitmentPhasePhase three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to existing treatments available for that cancer typeWho can participateClinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.For full inclusion / exclusion criteria refer to the Australian Clinical Trials Registry.
PIPOZA / J2N-MC-E009
Clonal Dynamics of Chronic Lymphocytic Leukemia Treated WithPirtobrutinib After Previous Treatment With Zanubrutinib
Trial IDNCT06812715Cancer typeChronic lymphocytic leukemiaStatusOpen to recruitmentPhasePhase Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer typesWho can participateClinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.For full inclusion / exclusion criteria refer to the Australian Clinical Trials Registry.
TLN-121-2501
An Open-Label, Multicenter, Phase 1/1b Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-121 as a Single Agent, and in Combination with Anti-lymphoma Agents in Patients with Relapsed or Refractory Non-Hodgkin Lymphomas
Trial IDNCT07082803Cancer typeRelapsed or refractory non-Hodgkin lymphomasStatusOpen to recruitmentPhasePhase one: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one clinical trial is to test the safety of the new treatment and find the best dose to give patientsWho can participateClinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.For full inclusion / exclusion criteria refer to the Australian Clinical Trials Registry.
PROTAC CLL
A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies
Trial ID
NCT05006716
Cancer type
B-cell malignancies
Status
Open and recruiting
Phase
Phase one: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one clinical trial is to test the safety of the new treatment and find the best dose to give patients
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
ReVenG
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Venetoclax-Obinutuzumab Retreatment in Patients With Recurring Chronic Lymphocytic Leukemia
Trial ID
NCT04895436
Cancer type
Chronic lymphocytic leukemia
Status
Open and recruiting
Phase
Phase Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
GoldiLox
An Open-label, Single-arm, Phase 2 Trial of GlOfitamab anD pIrtobrutinib (LOXo-305) in Patients With Mantle Cell Lymphoma and Prior Exposure to a BTK Inhibitor
Trial ID
NCT05833763
Cancer type
Mantle cell lymphoma
Status
Open and recruiting
Phase
Phase Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to ClinicalTrials.gov.
EPCORE-FL-2
A Phase 3, Multicenter, Randomized, Open-Label Trial of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Evaluate the Safety and Efficacy of Chemoimmunotherapy in Previously Untreated Follicular Lymphoma
Trial ID
NCT06191744
Cancer type
Follicular lymphoma
Status
Open and recruiting
Phase
Phase three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to existing treatments available for that cancer type
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
If you don’t find what you are looking for or would like a center closer to home that may also provide similar clinical trials, refer to the Victorian Cancer Trials Link or Australian Clinical Trials Registry.
